Anavar 10 mg 50 Tabs Saxon Pharma USA
$99.00
Product Short Description
Anavar 10 mg 50 Tabs Saxon Pharma USA deliversΒ oxandroloneΒ (C19H30O3), the 17Ξ±-ethyl-ΞΒΉ-DHT derivative exhibiting mild anabolic activity (~322-630:24 ratio) with minimal androgenicity, at exact 10 mg strength identical to historical Oxandrin tablets. Domestic U.S. production eliminates customs exposure servingΒ DEA Schedule IIIΒ compliant institutional channels through verified performance networks.β
Product Overview
Saxon Pharma USA’s Anavar 10 mg presentsΒ oxandrolone, featuring unique 2-oxa lactone ring conferring exceptional oral bioavailability (~9-10 hour half-life) and low hepatotoxicity profile among 17Ξ±-alkylated steroids, in small oval white scored tablets precisely replicatingΒ Oxandrin (BTG)Β morphology for institutional catalog integration across DEA-registered platforms. The 50-tablet HDPE bottle configuration supportsΒ CIII-compliant inventory reconciliationΒ under 21 CFR 1304.22 requiring detailed Schedule III tracking for institutional handlers.β
U.S.-domiciled GMP manufacturingΒ maintains molecular specifications (MW 306.44) matching FDA reference standards while distinguishing legitimate Schedule III pedigree from underground powder conversions exhibiting characteristic under-dosing. This authentic presentation serves institutional buyers requiringΒ Form 222 triplicate documentationΒ across U.S. jurisdictions, eliminating international sourcing risks.β
Saxon Anavar positions exclusively withinΒ verified DEA Schedule III ecosystemsΒ targeting licensed institutional clientele underΒ 21 CFR 1301.13 registrant requirements.
Brand & Manufacturer Information
Saxon Pharma USAΒ manufactures DEA Schedule III controlled substances through domestic GMP facilities serving institutional performance networks requiringΒ DEA registrant verification. Anavar 10 mg anchors Saxon’s mild oral anabolic catalog alongside Primo/Winstrol maintaining dosage standardization while authenticating supply chain legitimacy versus powder-pressed alternatives rejected by institutional handlers.
Domestic warehousing supportsΒ Form 222 platformsΒ eliminating customs risk while serialized batch documentation verifies 10 mg potency distinguishing Saxon from non-pharmaceutical origins.
Active Compound Information
ContainsΒ oxandroloneΒ (17Ξ²-hydroxy-17Ξ±-methyl-2-oxa-5Ξ±-androstan-3-one), exhibitingΒ 2-oxa lactone modificationΒ conferring 6x testosterone anabolic potency with 0.3x androgenic activity characteristic of DHT-derived 17Ξ±-alkyl steroids enabling oral bioavailability without 17Ξ±-methyl hepatotoxicity.Β DEA Schedule IIIΒ classification reflects lipid profile alteration potential and mild virilization risk profile supporting extended administration.β
10 mg strength matchesΒ historical Oxandrin 10 mg (NDC 54487-454-30)Β reference while 50-tablet count supports institutional packaging. Molecular formula C19H30O3;Β WADA S1.1a prohibitedΒ globally.β
Product Specifications
| Specification | Details |
|---|---|
| Product Name | Anavar 10 mg 50 Tabs Saxon Pharma USA |
| Active Compound | Oxandrolone (C19H30O3)Β β |
| Strength | 10 mg per oval scored tabletΒ β |
| Quantity | 50 tablets per HDPE bottle |
| Form | Oral scored tablets (Oxandrin equivalent) |
| Category | DEA Schedule III controlled substance |
| Appearance | White, oval, single-scored |
| Molecular Weight | 306.44 g/molΒ β |
| Half-Life | ~9-10 hours |
| Label Elements | “10 mg”, CIII warnings, serialized lot |
Quality Control & Testing Standards
10 mg oxandroloneΒ mandatesΒ USP <621> potency assayΒ (HPLC 95-105%),Β USP <711> dissolution,Β USP <905> uniformity, andΒ lactone ring verificationΒ confirming pharmaceutical-grade specifications matching Oxandrin monographs. Saxon batch records documentΒ C19H30O3 identityΒ distinguishing GMP production from underground conversions.β
50-tablet CIII configurationΒ incorporates USP <671> HDPE barriers with child-resistant closure satisfyingΒ 21 CFR 310.310(a). Stability maintainsΒ ICH Q1A(R2)Β 36-month shelf-life.
Intended Use & Market Positioning
Anavar 10 mg servesΒ DEA-registered CIII institutional researchersΒ managing mild-potencyΒ Schedule III anabolic inventoriesΒ through encrypted fulfillment requiringΒ Form 222 accountability. Serves verified institutional clientele exclusively.
Zero protocols, cycles, or outcomes representedΒ maintaining commercial CIII positioning.
Legal & Regulatory Disclaimer
Oxandrolone constitutes DEA Schedule IIIΒ underΒ 21 USC Β§812; non-medical handling violates Controlled Substances Act (5 years/$250,000 penalties).Β Institutional buyers assume Form 222/DEA licensing liability;Β no medical claims provided.β
You must be logged in to post a review.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisqueΒ vestibulum amet elit ut volutpat.
Reviews
There are no reviews yet.